Last update:
Immunology news
Diseases, Conditions, Syndromes
Pulmonary fibrosis traced to key signaling pathway
Idiopathic pulmonary fibrosis (IPF) is a chronic disease in which healthy lung tissue is gradually replaced by scar tissue. While the early events that initiate this change are poorly understood, recent research suggests ...
1 hour ago
0
0
Diseases, Conditions, Syndromes
In pneumonia's tug-of-war, lung microbiome could tip the balance
Northwestern University scientists have potentially uncovered a previously unknown, hidden player in pneumonia. In a new study, scientists found the lungs' own microbial community, or microbiome, appears to influence how ...
1 hour ago
0
0
Immune system's 'on-off' switch may hold answers for cancer and autoimmunity
A single signaling pathway controls whether immune cells attack or befriend cells they encounter while patrolling our bodies, researchers at Stanford Medicine have found. Manipulating this pathway could allow researchers ...
1 hour ago
0
0
How the immune system stalls weight loss
Researchers at the University of California San Diego School of Medicine have uncovered a surprising new function for immune cells: preventing excess weight loss.
1 hour ago
0
0
Real-time imaging captures what happens to cancer cells arriving in the brain
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is ...
2 hours ago
0
0
Anxiety and insomnia may lower natural killer cell count, potentially repressing immune function
Natural killer (NK) cells are the bodyguards of our immune system. As a first line of defense, they destroy invading pathogens, foreign bodies, and infected cells in early stages, thereby preventing them from spreading. NK ...
12 hours ago
0
2
Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
4 hours ago
0
0
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy ...
4 hours ago
0
0
FDA approves expanded indication for Jaypirca
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
2 hours ago
0
0
Dietary restriction fuels T cells with ketones, boosting their cancer-fighting stamina
Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators. The findings lay the groundwork for developing dietary strategies ...
22 hours ago
0
14
Disarming cancer stem cells' shield makes immunotherapy more effective
Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, it works very well in shrinking tumors and sending cancer into remission, an undetectable state of ...
23 hours ago
0
0
Combination treatment shows large improvement in survival for people with relapsed myeloma
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
17 hours ago
0
1
Team discovers how to target 'undruggable' protein that fuels aggressive leukemia
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs—a discovery that could open the ...
22 hours ago
0
0
Experimental antibody enables lasting platelet stability in autoimmune bleeding condition
More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening ...
Dec 9, 2025
0
0
Researchers find vital clue in the progression of Type 1 diabetes
Type 1 diabetes is a disease in which the body mistakenly attacks itself as the immune system destroys the pancreas's insulin-producing cells. Why the immune system turns against these cells remains one of the enduring questions ...
Dec 9, 2025
0
0
Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
Dec 9, 2025
0
0
Ianalumab+standard therapy extends time to treatment failure in patients with previously treated immune thrombocytopenia
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard therapy went longer without a bleeding episode that needed urgent treatment or needing another treatment ...
Dec 9, 2025
0
0
Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge platform, ...
Dec 9, 2025
0
0
Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
0
Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
0
Home-based monitoring could transform care for patients receiving T-cell redirecting therapies
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
Dec 9, 2025
0
0
New data highlight promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
0
Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E antibodies in humanized mice, protects against Immunoglobulin E-mediated anaphylaxis, and shows no detectable ...
'Ready-made' T-cell gene therapy tackles 'incurable' T-cell leukemia
A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare ...
Dec 8, 2025
0
8
Immunotherapy works for sepsis thanks to precision approach
Immunotherapy for sepsis is effective when doctors tailor the treatment precisely to the patient's immune system condition. While earlier research showed little benefit of immunotherapy in sepsis, a new study demonstrates ...
Dec 8, 2025
0
19
